Related Experiment Video
Updated: Jun 9, 2026
07:40
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Cancer Innovation
|June 8, 2026
Summary
Poly ADP-ribose polymerase (PARP) inhibitors offer a new precision therapy for breast cancer by exploiting DNA repair defects. This consensus guides their safe and effective clinical use in China.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Breast cancer incidence is rising in China, increasing the need for advanced treatments.
- Poly ADP-ribose polymerase (PARP) inhibitors represent a novel therapeutic class targeting DNA damage repair.
- BRCA1/2 mutations are key indicators for PARP inhibitor efficacy in breast cancer.
Purpose of the Study:
- To provide guidance on the standardized application of PARP inhibitors in breast cancer treatment.
- To outline safety management strategies for PARP inhibitors in clinical practice.
- To serve as a reference for healthcare professionals based on current evidence.
Main Methods:
- Review of latest evidence-based medical data.
- Consensus development among experts.
- Focus on clinical application and safety.
Main Results:
- PARP inhibitors induce synthetic lethality in BRCA-mutated breast cancer cells.
- Approved PARP inhibitors like Olaparib and Fluzoparib show significant efficacy.
- Standardized application protocols are crucial for optimal outcomes.
Conclusions:
- PARP inhibitors are a valuable option for precision therapy in breast cancer.
- Evidence-based guidance is essential for safe and effective use.
- This consensus aims to improve breast cancer management in China.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...